Cancer Chemotherapy and Pharmacology

, Volume 22, Issue 4, pp 299–302 | Cite as

Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse

  • Robert T. Dorr
  • Michelle Soble
  • David S. Alberts
Original Articles Thiols, Alkylating Agents, Skin Toxicity, Thiosulfate


The highly vesicant nature of the alkylating anticancer agent mechlorethamine (HN2, or nitrogen mustard) requires careful i. v. technique during its administration. Skin toxicity due to HN2 extravasation is severe and typically prolonged over several months. Mouse skin toxicity studies were carried out to find a local antidote to decrease the severity of tissue damage by this agent. Intradermal (i.d.) HN2 (0.005–0.5 mg) caused dose-dependent skin ulcers in the mouse. Isotonic sodium thiosulfate Na2S2O3 (0.167 M) or hypertonic (0.34 M) Na2S2O3 (0.05 ml) given immediately after HN2 significantly reduced the mean HN2 ulceration area and the total time of ulceration. Ineffective local HN2 antidotes included hyaluronidase, hydrocortisone, and sodium chloride, all given i.d. Topical applications of DMSO, cold, and heat were also ineffective. Sodium thiosulfate is believed to chemically neutralize reactive mechlorethamine-alkylating species and thus decrease skin toxicity. Thiosulfate dosing studies showed that a molar excess of at least 200:1 (Na2S2O3:HN2) was required for significant antidotal activity. If thiosulfate treatment was delayed 4–24 h after HN2, no antidotal effects were obtained. We conclude that sodium thiosulfate can decrease the severity of local tissue damage caused by HN2. It should be considered the antidote of choice in the setting of clinical HN2 extravasations.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bonadonna G, Karnofsky DA (1965) Protection studies with sodium thiosulfate against methyl bis (B-chloroethyl) amince hydrochloride (HN2) and its ethyleimmonium derivative. Clin Pharmacol Ther 6(1): 50–64Google Scholar
  2. 2.
    Calabresi P, Parks RE (1975) Alkylating agents, antimetabolites, hormones, and other antiproliferative agents. In: Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics. MacMillan, New York, pp 1254–1262Google Scholar
  3. 3.
    Chait LA, Dinner MI (1975) Ulceration caused by cytotoxic drugs. S Afr Med J 49: 1935–1936Google Scholar
  4. 4.
    Dorr RT, Alberts DS, Chen HSG (1980) Experimental model of doxorubicin extravasation in the mouse. J Pharmacol Methods 4(4): 321–334Google Scholar
  5. 5.
    Dorr RT, Alberts DS, Stone A (1985) Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. Cancer Treat Rep 69: 431–437Google Scholar
  6. 6.
    Gilman A (1963) The initial clinical trial of nitrogen mustard. Am J Surg 105: 574–578Google Scholar
  7. 7.
    Goodman L, Wintrobe M, Dameshek W, Goodman MJ, Gilman A, McLennan MT (1946) Nitrogen mustard therapy. J Am Med Assoc 132(3): 126–132Google Scholar
  8. 8.
    Hatiboglu I, Mihich E, Moore GE, Nichol CA (1962) Use of sodium thiosulfate as a neutralizing agent during regional administration of nitrogen mustard: An experimental study. Ann Surg 156(6): 994–1001Google Scholar
  9. 9.
    Litwins J, Boyd JJ, Greenwald L (1943) Action of sodium thiosulfate on blood. Exp Med Surg 1: 252–259Google Scholar
  10. 10.
    Merck, Sharpe and Dohme Company, Mustargen official prescribing information. (1985) Physician desk reference, 39th edn. Medical Economics Co, Oradell, NJ, pp 1337–1339Google Scholar
  11. 11.
    Nie NH, Hill CH, Jenkins JG, Steinbrenner K, Bent DH (1975) Statistical packages for the social services. McGraw-Hill, New York, pp 422–430Google Scholar
  12. 12.
    Ogston A, Holiday J, Philpot J, Stocken LA (1984) The replacement reactions of beta dichlorethyl sulphide and of some analogous in aqueous solution: The isolation of beta chloro beta hydroxyl diethyl sulphide. Trans Faraday Soc 44: 45PubMedGoogle Scholar
  13. 13.
    Owen OE, Dellatorre DL, Van Scott EJ, Cohen MR (1980) Accidental intramuscular injection of mechlorethamine. Cancer 45: 2225–2226Google Scholar
  14. 14.
    Owens G, Hatiboglu I (1961) Clinical evaluation of sodium thiosulfate, a systemic neutralizer of nitrogen mustard. Ann Surg 154: 895–897Google Scholar
  15. 15.
    Shea M, Koziol JA, Howell SB (1984) Kinetics of sodium thiosulfate, a cisplatin neutralizer. Clin Pharmacol Ther 35(3): 419–425Google Scholar
  16. 16.
    Van Scott EJ, Kimanson JD (1973) Complete remission of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Cancer 32: 18–30Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Robert T. Dorr
    • 1
    • 2
  • Michelle Soble
    • 1
    • 2
  • David S. Alberts
    • 1
    • 2
  1. 1.Section of Hematology and Oncology, Department of MedicineThe University of ArizonaTusconUSA
  2. 2.Arizona Cancer Center, College of MedicineThe University of ArizonaTusconUSA

Personalised recommendations